Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab OLE in Psoriatic Arthritis
NCT02986373Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in psoriatic arthritis (PsA), sponsored by AbbVie Inc. Primary endpoint: Number of Participants With Adverse Events up to 56 weeks. Started Dec 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02986373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986373.